Lantern Pharma Inc (LTRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lantern Pharma Inc (LTRN) has a cash flow conversion efficiency ratio of 0.914x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.94 Million) by net assets ($-3.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LTRN stock market capitalisation for the company's overall valuation and market capitalisation.
Lantern Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lantern Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lantern Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lantern Pharma Inc ranked by their cash flow conversion efficiency. See Lantern Pharma Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Music Broadcast Limited
NSE:RADIOCITY
|
0.017x |
|
Noumi Ltd
AU:NOU
|
-0.029x |
|
Golden Heaven Group Holdings Ltd. Ordinary Shares
NASDAQ:GDHG
|
0.020x |
|
Able View Global Inc. Class B Ordinary Shares
NASDAQ:ABLV
|
-0.121x |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
0.211x |
|
Is Girisim Sermayesi Yatirim Ortakligi AS
IS:ISGSY
|
-0.007x |
|
FibroBiologics, Inc. Common Stock
NASDAQ:FBLG
|
-31.776x |
|
Maheshwari Logistics Limited
NSE:MAHESHWARI
|
-0.131x |
Annual Cash Flow Conversion Efficiency for Lantern Pharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lantern Pharma Inc from 2018 to 2025. View Lantern Pharma Inc (LTRN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.53 Million | $-15.68 Million | -2.399x | -185.37% |
| 2024-12-31 | $21.19 Million | $-17.81 Million | -0.841x | -139.73% |
| 2023-12-31 | $40.91 Million | $-14.35 Million | -0.351x | -53.93% |
| 2022-12-31 | $56.04 Million | $-12.77 Million | -0.228x | -53.96% |
| 2021-12-31 | $71.57 Million | $-10.59 Million | -0.148x | +48.42% |
| 2020-12-31 | $19.70 Million | $-5.65 Million | -0.287x | +87.28% |
| 2019-12-31 | $943.28K | $-2.13 Million | -2.256x | -135.80% |
| 2018-12-31 | $-201.80K | $-1.27 Million | 6.301x | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more